Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Gemcitabine + Cisplatin in Recurrent/Metastatic NPC
NCT03121716Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2017
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Hengrui. Primary endpoint: progression of disease at 28 days. Started Apr 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03121716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121716.